soul trial oral semaglutide cardiovascular outcomes nejm 2025 results A emulation in Nature Medicine shows that treatment with and tirzepatide showed similar levels of benefit on in people at elevated cardiovascular risk with obesity and diabetes. Link Trial Scorecard: SOUL
Description
Discover what current evidence reveals about semaglutide and cognitive health, including potential neuroprotective effects, dementia risk factors in type 2 diabetes, and when to consult your GP about memory concerns.
Participants experienced an average weight loss of 12-24% over 48 weeks
You are not choosing between cardio and strength
[The research was fielded between December 30, 2024 and January 7, 2025]
But questions remain about who should take them.
You can find more information about your Meritain Health insurance, get support from our service specialists, and more when you log in.
